Zoledronic acid enhances tumor growth and metastatic spread in a mouse model of jaw osteosarcoma.
bisphosphonates
bone resorption
mandible
osteosarcoma
tumor microenvironment
Journal
Oral diseases
ISSN: 1601-0825
Titre abrégé: Oral Dis
Pays: Denmark
ID NLM: 9508565
Informations de publication
Date de publication:
20 Feb 2024
20 Feb 2024
Historique:
revised:
08
01
2024
received:
21
10
2023
accepted:
06
02
2024
medline:
20
2
2024
pubmed:
20
2
2024
entrez:
20
2
2024
Statut:
aheadofprint
Résumé
Investigation of the therapeutic effect of zoledronic acid (ZA) in a preclinical model of jaw osteosarcoma (JO). The effect of 100 μg/kg ZA administered twice a week was assessed in a xenogenic mouse model of JO. The clinical (tumor growth, development of lung metastasis), radiological (bone microarchitecture by micro-CT analysis), and molecular and immunohistochemical (TRAP, RANK/RANKL, VEGF, and CD146) parameters were investigated. Animals receiving ZA exhibited an increased tumor volume compared with nontreated animals (71.3 ± 14.3 mm The use of bisphosphonates in the therapeutic strategy for JO should be further explored, as should the role of bone resorption in the pathophysiology of the disease.
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Centre Hospitalier Universitaire de Nantes
Organisme : Fondation des Gueules Cassées
ID : 2018-51
Informations de copyright
© 2024 The Authors. Oral Diseases published by Wiley Periodicals LLC.
Références
Alfranca, A., Martinez-Cruzado, L., Tornin, J., Abarrategi, A., Amaral, T., de Alava, E., Menendez, P., Garcia-Castro, J., & Rodriguez, R. (2015). Bone microenvironment signals in osteosarcoma development. Cellular and Molecular Life Sciences, 72, 3097-3113.
Baumhoer, D., Brunner, P., Eppenberger-Castori, S., Smida, J., Nathrath, M., & Jundt, G. (2014). Osteosarcomas of the jaws differ from their peripheral counterparts and require a distinct treatment approach. Experiences from the DOESAK registry. Oral Oncology, 50, 147-153.
Bertin, H., Gomez-Brouchet, A., & Rédini, F. (2020). Osteosarcoma of the jaws: An overview of the pathophysiological mechanisms. Critical Reviews in Oncology/Hematology, 156, 103126.
Bertin, H., Guilho, R., Brion, R., Amiaud, J., Battaglia, S., Moreau, A., Brouchet-Gomez, A., Longis, J., Piot, B., Heymann, D., Corre, P., & Rédini, F. (2019). Jaw osteosarcoma models in mice: First description. Journal of Translational Medicine, 17, 56.
Bertin, H., Peries, S., Amiaud, J., van Acker, N., Perrot, B., Bouvier, C., Aubert, S., Marie, B., Larousserie, F., de Pinieux, G., Crenn, V., Rédini, F., & Gomez-Brouchet, A. (2023). Characterization of the tumor microenvironment in jaw osteosarcomas, towards prognostic markers and new therapeutic targets. Cancers (Basel), 15, 1004.
Bialick, S., Campoverde, L., Gallegos, J. A. O., Barreto-Coelho, P., Watson, A., Arora, K., Perez, A., Lopez, E., Venkat, S., Rosenberg, A. E., Crawford, B., Jonczak, E., Trent, J., Dhir, A., & D'Amato, G. (2023). Osteogenic sarcoma of the head and neck: Is chemotherapy needed? Current Treatment Options in Oncology, 24, 528-541.
Biteau, K., Guiho, R., Chatelais, M., Taurelle, J., Chesneau, J., Corradini, N., Heymann, D., & Redini, F. (2016). L-MTP-PE and zoledronic acid combination in osteosarcoma: Preclinical evidence of positive therapeutic combination for clinical transfer. American Journal of Cancer Research, 6, 677-689.
Boon, E., van der Graaf, W. T. A., Gelderblom, H., Tesselaar, M. E. T., van Es, R. J. J., Oosting, S. F., de Bree, R., van Meerten, E., Hoeben, A., Smeele, L. E., Willems, S. M., Witjes, M. J. H., Buter, J., Baatenburg de Jong, R. J., Flucke, U. E., Peer, P. G. M., Bovée, J. V. M. G., & van Herpen, C. M. L. (2017). Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults. Head & Neck, 39, 140-146.
Boopathi, E., Birbe, R., Shoyele, S. A., Den, R. B., & Thangavel, C. (2022). Bone health Management in the Continuum of prostate cancer disease. Cancers (Basel), 14, 4305.
Bouaoud, J., Beinse, G., Epaillard, N., Amor-Sehlil, M., Bidault, F., Brocheriou, I., Hervé, G., Spano, J. P., Janot, F., Boudou-Rouquette, P., Benassarou, M., Schouman, T., Goudot, P., Malouf, G., Goldwasser, F., & Bertolus, C. (2019). Lack of efficacy of neoadjuvant chemotherapy in adult patients with maxillo-facial high-grade osteosarcomas: A French experience in two reference centers. Oral Oncology, 95, 79-86.
Bouxsein, M. L., Boyd, S. K., Christiansen, B. A., Guldberg, R. E., Jepsen, K. J., & Müller, R. (2010). Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. Journal of Bone and Mineral Research, 25, 1468-1486.
Cappariello, A., & Rucci, N. (2019). Tumour-derived extracellular vesicles (EVs): A dangerous ‘message in a bottle’ for bone. International Journal of Molecular Sciences, 20, 4805.
Crenn, V., Biteau, K., Amiaud, J., Dumars, C., Guiho, R., Vidal, L., Nail, L. L., Heymann, D., Moreau, A., Gouin, F., & Redini, F. (2017). Bone microenvironment has an influence on the histological response of osteosarcoma to chemotherapy: Retrospective analysis and preclinical modeling. American Journal of Cancer Research, 7, 2333-2349.
Curtis, R. C., Custis, J. T., Ehrhart, N. P., Ehrhart, E. J., Condon, K. W., Gookin, S. E., & Donahue, S. W. (2016). Combination therapy with zoledronic acid and parathyroid hormone improves bone architecture and strength following a clinically-relevant dose of stereotactic radiation therapy for the local treatment of canine osteosarcoma in athymic rats. PLoS One, 11, e0158005.
Dass, C. R., & Choong, P. F. M. (2007). Zoledronic acid inhibits osteosarcoma growth in an orthotopic model. Molecular Cancer Therapeutics, 6, 3263-3270.
Di Salvatore, M., Orlandi, A., Bagalà, C., Quirino, M., Cassano, A., Astone, A., & Barone, C. (2011). Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line. Cell Proliferation, 44, 139-146.
Endo-Munoz, L., Cumming, A., Rickwood, D., Wilson, D., Cueva, C., Ng, C., Strutton, G., Cassady, A. I., Evdokiou, A., Sommerville, S., Dickinson, I., Guminski, A., & Saunders, N. A. (2010). Loss of osteoclasts contributes to development of osteosarcoma pulmonary metastases. Cancer Research, 70, 7063-7072.
Endo-Munoz, L., Evdokiou, A., & Saunders, N. A. (2012). The role of osteoclasts and tumour-associated macrophages in osteosarcoma metastasis. Biochimica et Biophysica Acta, 1826, 434-442.
Fu, D., He, X., Yang, S., Xu, W., Lin, T., & Feng, X. (2011). Zoledronic acid inhibits vasculogenic mimicry in murine osteosarcoma cell line in vitro. BMC Musculoskeletal Disorders, 12, 146.
Gomez-Brouchet, A., Gilhodes, J., Acker, N. V., Brion, R., Bouvier, C., Assemat, P., Gaspar, N., Aubert, S., Guinebretiere, J. M., Marie, B., Larousserie, F., Entz-Werlé, N., Pinieux, G., Mascard, E., Gouin, F., Brousset, P., Tabone, M. D., Jimenez, M., Le Deley, M. C., … Rédini, F. (2021). Characterization of macrophages and osteoclasts in the osteosarcoma tumor microenvironment at diagnosis: New perspective for osteosarcoma treatment? Cancers (Basel), 13, 423.
Gomez-Brouchet, A., Illac, C., Gilhodes, J., Bouvier, C., Aubert, S., Guinebretiere, J. M., Marie, B., Larousserie, F., Entz-Werlé, N., de Pinieux, G., Filleron, T., Minard, V., Minville, V., Mascard, E., Gouin, F., Jimenez, M., Ledeley, M. C., Piperno-Neumann, S., Brugieres, L., & Rédini, F. (2017). CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: An immunohistochemical analysis of the biopsies fromthe French OS2006 phase 3 trial. Oncoimmunology, 6, e1331193.
Gomez-Brouchet, A., Mascard, E., Siegfried, A., de Pinieux, G., Gaspar, N., Bouvier, C., Aubert, S., Marec-Bérard, P., Piperno-Neumann, S., Marie, B., Larousserie, F., Galant, C., Fiorenza, F., Anract, P., Sales de Gauzy, J., & Gouin, F. (2019). Assessment of resection margins in bone sarcoma treated by neoadjuvant chemotherapy: Literature review and guidelines of the bone group (GROUPOS) of the French sarcoma group and bone tumor study group (GSF-GETO/RESOS). Orthopaedics & Traumatology, Surgery & Research, 105, 773-780.
Granowski-LeCornu, M., Chuang, S.-K., Kaban, L. B., & August, M. (2011). Osteosarcoma of the jaws: Factors influencing prognosis. Journal of Oral and Maxillofacial Surgery, 69, 2368-2375.
Heymann, D., Fortun, Y., Rédini, F., & Padrines, M. (2005). Osteolytic bone diseases: Physiological analogues of bone resorption effectors as alternative therapeutic tools. Drug Discovery Today, 10, 242-247.
Heymann, D., Ory, B., Blanchard, F., Heymann, M. F., Coipeau, P., Charrier, C., Couillaud, S., Thiery, J. P., Gouin, F., & Redini, F. (2005). Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. Bone, 37, 74-86.
Heymann, D., Ory, B., Gouin, F., Green, J. R., & Rédini, F. (2004). Bisphosphonates: New therapeutic agents for the treatment of bone tumors. Trends in Molecular Medicine, 10, 337-343.
Heymann, M.-F., Lézot, F., & Heymann, D. (2019). The contribution of immune infiltrates and the local microenvironment in the pathogenesis of osteosarcoma. Cellular Immunology, 343, 103711.
Heymann, M.-F., Lezot, F., & Heymann, D. (2020). Bisphosphonates in common pediatric and adult bone sarcomas. Bone, 139, 115523.
Ishikawa, T. (2023). Differences between zoledronic acid and denosumab for breast cancer treatment. Journal of Bone and Mineral Metabolism, 41, 301-306.
Jawad, S. N., & Abdullah, B. H. (2010). Proliferative, apoptotic and angiogenic potentials in jaws and long bones osteosarcomas: A comparative immunohistochemical study. Journal of Oral Pathology & Medicine, 39, 681-686.
Junankar, S., Shay, G., Jurczyluk, J., Ali, N., Down, J., Pocock, N., Parker, A., Nguyen, A., Sun, S., Kashemirov, B., McKenna, C. E., Croucher, P. I., Swarbrick, A., Weilbaecher, K., Phan, T. G., & Rogers, M. J. (2015). Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancer. Cancer Discovery, 5, 35-42.
Kaya, M., Wada, T., Akatsuka, T., Kawaguchi, S., Nagoya, S., Shindoh, M., Higashino, F., Mezawa, F., Okada, F., & Ishii, S. (2000). Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clinical Cancer Research, 6, 572-577.
Khadembaschi, D., Jafri, M., Praveen, P., Parmar, S., & Breik, O. (2022). Does neoadjuvant chemotherapy provide a survival benefit in maxillofacial osteosarcoma: A systematic review and pooled analysis. Oral Oncology, 135, 106133.
Kontio, R., Hagström, J., Lindholm, P., Böhling, T., Sampo, M., Mesimäki, K., Saarilahti, K., Koivunen, P., & Mäkitie, A. A. (2019). Craniomaxillofacial osteosarcoma - The role of surgical margins. Journal of Cranio-Maxillo-Facial Surgery, 47, 922-925.
Krishnamurthy, A., & Palaniappan, R. (2018). Osteosarcomas of the head and neck region: A case series with a review of literature. Journal of Maxillofacial and Oral Surgery, 17, 38-43.
Labrinidis, A., Hay, S., Liapis, V., Findlay, D. M., & Evdokiou, A. (2010). Zoledronic acid protects against osteosarcoma-induced bone destruction but lacks efficacy against pulmonary metastases in a syngeneic rat model. International Journal of Cancer, 127, 345-354.
Labrinidis, A., Hay, S., Liapis, V., Ponomarev, V., Findlay, D. M., & Evdokiou, A. (2009). Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model. Clinical Cancer Research, 15, 3451-3461.
Lee, R. J., Arshi, A., Schwartz, H. C., & Christensen, R. E. (2015). Characteristics and prognostic factors of osteosarcoma of the jaws: A retrospective cohort study. JAMA Otolaryngology. Head & Neck Surgery, 141, 470-477.
Li, H.-S., Lei, S.-Y., Li, J.-L., Xing, P. Y., Hao, X. Z., Xu, F., Xu, H. Y., & Wang, Y. (2022). Efficacy and safety of concomitant immunotherapy and denosumab in patients with advanced non-small cell lung cancer carrying bone metastases: A retrospective chart review. Frontiers in Immunology, 13, 908436.
Li, S., Chen, P., Pei, Y., Zheng, K., Wang, W., Qiu, E., & Zhang, X. (2019). Addition of zoledronate to chemotherapy in patients with osteosarcoma treated with limb-sparing surgery: A phase III clinical trial. Medical Science Monitor, 25, 1429-1438.
Marec-Berard, P., Laurence, V., Occean, B.-V., Ray-Coquard, I., Linassier, C., Corradini, N., Collard, O., Chaigneau, L., Cupissol, D., Kerbrat, P., Saada-Bouzid, E., Delcambre, C., Gouin, F., Guillemet, C., Jimenez, M., Lervat, C., Gaspar, N., le Deley, M. C., Brugieres, L., & Piperno-Neumann, S. (2020). Methotrexate-etoposide-Ifosfamide compared with doxorubicin-cisplatin-Ifosfamide chemotherapy in osteosarcoma treatment, patients aged 18-25 years. Journal of Adolescent and Young Adult Oncology, 9, 172-182.
Mirabello, L., Zhu, B., Koster, R., Karlins, E., Dean, M., Yeager, M., Gianferante, M., Spector, L. G., Morton, L. M., Karyadi, D., Robison, L. L., Armstrong, G. T., Bhatia, S., Song, L., Pankratz, N., Pinheiro, M., Gastier-Foster, J. M., Gorlick, R., de Toledo, S. R. C., … Savage, S. A. (2020). Frequency of pathogenic germline variants in cancer-susceptibility genes in patients with osteosarcoma. JAMA Oncology, 6, 724-734.
Navet, B., Ando, K., Vargas-Franco, J. W., Brion, R., Amiaud, J., Mori, K., Yagita, H., Mueller, C., Verrecchia, F., Dumars, C., Heymann, M. F., Heymann, D., & Lézot, F. (2018). The intrinsic and extrinsic implications of RANKL/RANK signaling in osteosarcoma: From tumor initiation to lung metastases. Cancers (Basel), 10, 398.
Nissanka, E. H., Amaratunge, E. A. P. D., & Tilakaratne, W. M. (2007). Clinicopathological analysis of osteosarcoma of jaw bones. Oral Diseases, 13, 82-87.
Ory, B., Heymann, M.-F., Kamijo, A., Gouin, F., Heymann, D., & Redini, F. (2005). Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer, 104, 2522-2529.
Percie du Sert, N., Hurst, V., Ahluwalia, A., Alam, S., Avey, M. T., Baker, M., Browne, W. J., Clark, A., Cuthill, I. C., Dirnagl, U., Emerson, M., Garner, P., Holgate, S. T., Howells, D. W., Karp, N. A., Lazic, S. E., Lidster, K., MacCallum, C. J., Macleod, M., … Würbel, H. (2020). The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. BMJ Open Science, 4, e100115.
Piperno-Neumann, S., Le Deley, M.-C., Rédini, F., Pacquement, H., Marec-Bérard, P., Petit, P., Brisse, H., Lervat, C., Gentet, J. C., Entz-Werlé, N., Italiano, A., Corradini, N., Bompas, E., Penel, N., Tabone, M. D., Gomez-Brouchet, A., Guinebretière, J. M., Mascard, E., Gouin, F., … French Sarcoma Group (GSF-GETO). (2016). Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): A randomised, multicentre, open-label, phase 3 trial. The Lancet Oncology, 17, 1070-1080.
Piperno-Neumann, S., Ray-Coquard, I., Occean, B.-V., Laurence, V., Cupissol, D., Perrin, C., Penel, N., Bompas, E., Rios, M., le Cesne, A., Italiano, A., Anract, P., de Pinieux, G., Collard, O., Bertucci, F., Duffaud, F., le Deley, M. C., Delaye, J., Brugieres, L., & Blay, J. Y. (2020). Results of API-AI based regimen in osteosarcoma adult patients included in the French OS2006/Sarcome-09 study. International Journal of Cancer, 146, 413-423.
Salaroglio, I. C., Campia, I., Kopecka, J., Gazzano, E., Orecchia, S., Ghigo, D., & Riganti, C. (2015). Zoledronic acid overcomes chemoresistance and immunosuppression of malignant mesothelioma. Oncotarget, 6, 1128-1142.
Santini, D., Vincenzi, B., Dicuonzo, G., Avvisati, G., Massacesi, C., Battistoni, F., Gavasci, M., Rocci, L., Tirindelli, M. C., Altomare, V., Tocchini, M., Bonsignori, M., & Tonini, G. (2003). Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clinical Cancer Research, 9, 2893-2897.
Schneider, C. A., Rasband, W. S., & Eliceiri, K. W. (2012). NIH image to ImageJ: 25 years of image analysis. Nature Methods, 9, 671-675.
Scotlandi, K., Hattinger, C. M., Pellegrini, E., Gambarotti, M., & Serra, M. (2020). Genomics and therapeutic vulnerabilities of primary bone tumors. Cell, 9, 968.
Seidensaal, K., Dostal, M., Liermann, J., Adeberg, S., Weykamp, F., Schmid, M. P., Freudlsperger, C., Hoffmann, J., Hompland, I., Herfarth, K., Debus, J., & Harrabi, S. B. (2022). Inoperable or incompletely resected craniofacial osteosarcoma treated by particle radiotherapy. Frontiers in Oncology, 12, 927399.
Thariat, J., Julieron, M., Brouchet, A., Italiano, A., Schouman, T., Marcy, P. Y., Odin, G., Lacout, A., Dassonville, O., Peyrottes-Birstwisles, I., Miller, R., Thyss, A., & Isambert, N. (2012). Osteosarcomas of the mandible: Are they different from other tumor sites? Critical Reviews in Oncology/Hematology, 82, 280-295.
Thariat, J., Schouman, T., Brouchet, A., Sarini, J., Miller, R. C., Reychler, H., Ray-Coquard, I., Italiano, A., Verite, C., Sohawon, S., Bompas, E., Dassonville, O., Salas, S., Aldabbagh, K., Maingon, P., de la MotteRouge, T., Kurtz, J. E., Usseglio, J., Kerbrat, P., … Julieron, M. (2013). Osteosarcomas of the mandible: Multidisciplinary management of a rare tumor of the young adult a cooperative study of the GSF-GETO, rare cancer network, GETTEC/REFCOR and SFCE. Annals of Oncology, 24, 824-831.
van den Berg, H., & Merks, J. H. M. (2013). Incidence and grading of cranio-facial osteosarcomas. International Journal of Oral and Maxillofacial Surgery, 43, 7-12.
Verrecchia, F., & Rédini, F. (2018). Transforming growth factor-β signaling plays a pivotal role in the interplay between osteosarcoma cells and their microenvironment. Frontiers in Oncology, 8, 133.
Wang, J., Wu, Z., Zheng, M., Yu, S., Zhang, X., & Xu, X. (2022). CD146 is closely associated with the prognosis and molecular features of osteosarcoma: Guidance for personalized clinical treatment. Frontiers in Genetics, 13, 1025306.
Weber, V., Stigler, R., Lutz, R., Kesting, M., & Weber, M. (2023). Systematic review of craniofacial osteosarcoma regarding different clinical, therapeutic and prognostic parameters. Frontiers in Oncology, 13, 1006622.
Wolfe, T. D., Pillai, S. P. S., Hildreth, B. E., Lanigan, L. G., Martin, C. K., Werbeck, J. L., & Rosol, T. J. (2011). Effect of zoledronic acid and amputation on bone invasion and lung metastasis of canine osteosarcoma in nude mice. Clinical & Experimental Metastasis, 28, 377-389.
Wu, T., & Dai, Y. (2017). Tumor microenvironment and therapeutic response. Cancer Letters, 387, 61-68.
Yu, L., Zhang, J., & Li, Y. (2022). Effects of microenvironment in osteosarcoma on chemoresistance and the promise of immunotherapy as an osteosarcoma therapeutic modality. Frontiers in Immunology, 13, 871076.
Zekri, J., Mansour, M., & Karim, S. M. (2014). The anti-tumour effects of zoledronic acid. Journal of Bone Oncology, 3, 25-35.
Zhu, T., Han, J., Yang, L., Cai, Z., Sun, W., Hua, Y., & Xu, J. (2022). Immune microenvironment in osteosarcoma: Components, therapeutic strategies and clinical applications. Frontiers in Immunology, 13, 907550.